Alkermes (ALKS) Projected to Announce Earnings on Tuesday

Alkermes (NASDAQ:ALKS) will likely be issuing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Alkermes to announce earnings of ($0.04) per share and revenue of $458.7190 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Alkermes Stock Down 1.9%

Shares of ALKS stock opened at $51.72 on Tuesday. The stock’s 50-day simple moving average is $45.76 and its 200-day simple moving average is $36.81. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.70 and a current ratio of 2.27. The firm has a market capitalization of $8.62 billion, a PE ratio of 57.47 and a beta of 0.34. Alkermes has a fifty-two week low of $25.17 and a fifty-two week high of $55.67.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Weiss Ratings lowered Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Bank of America restated an “underperform” rating on shares of Alkermes in a research note on Monday, June 29th. Wells Fargo & Company upped their price objective on shares of Alkermes from $44.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, June 29th. Truist Financial upgraded shares of Alkermes to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $63.00 target price (up from $45.00) on shares of Alkermes in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $52.50.

Insider Activity

In other Alkermes news, Director Christopher I. Wright sold 2,000 shares of Alkermes stock in a transaction on Friday, June 12th. The shares were sold at an average price of $45.10, for a total value of $90,200.00. Following the completion of the transaction, the director owned 25,680 shares of the company’s stock, valued at approximately $1,158,168. The trade was a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $43.05, for a total transaction of $87,563.70. Following the completion of the transaction, the executive vice president owned 229,524 shares of the company’s stock, valued at approximately $9,881,008.20. This trade represents a 0.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 35,102 shares of company stock valued at $1,494,410 in the last three months. 4.59% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alkermes

Several institutional investors and hedge funds have recently modified their holdings of ALKS. State Street Corp grew its holdings in Alkermes by 10.9% in the fourth quarter. State Street Corp now owns 9,472,858 shares of the company’s stock valued at $265,051,000 after purchasing an additional 932,507 shares during the period. Renaissance Technologies LLC lifted its position in shares of Alkermes by 6.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,668,028 shares of the company’s stock valued at $186,571,000 after buying an additional 375,500 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Alkermes by 32.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock valued at $145,064,000 after buying an additional 1,256,377 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Alkermes by 19.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,412,783 shares of the company’s stock valued at $123,467,000 after acquiring an additional 714,787 shares during the period. Finally, Holocene Advisors LP increased its holdings in Alkermes by 31.2% in the 2nd quarter. Holocene Advisors LP now owns 2,853,768 shares of the company’s stock worth $81,646,000 after acquiring an additional 679,166 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.